Loading
companiesCompany
PharmaMar
Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin.
Overview
PharmaMar, based in Madrid and listed as PHM.MC, is the Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin. It discovered lurbinectedin, sold as Zepzelca and partnered with Jazz in the United States, and trabectedin, sold as Yondelis, and the success of the IMforte trial in 2025 broadened lurbinectedin from relapsed small-cell lung cancer into first-line maintenance. OnCo links it to small-cell lung cancer, Ewing sarcoma and soft tissue sarcomas, and to the lurbinectedin drug record. Whether marine-derived transcription inhibitors can find further indications, or whether lurbinectedin remains its last major product, is the open question. Lurbinectedin has its own page.
Headquarters
Madrid, ES
Scorecard
All companies#189of 1244 companies, score 31
- approved products +6
- targets +2
- modalities +2
- regions +3
- 24-month regulatory events +2
- registry trials +16
1 approved, 0 in phase 3, 0 earlier, 1 targets, 63 registry studies. Formula on the scorecards page.
Type
Biotech · PHM.MC
Stage
Public
Website
ApprovedCytotoxic (transcription inhibitor)
Lurbinectedin · Zepzelca
A marine-derived chemotherapy that jams cancer's gene-reading machinery, approved for relapsed small-cell lung cancer and, since 2025, as first-line maintenance with atezolizumab.
EstablishedMarine-derived cyclic depsipeptide (small molecule), intravenous
Plitidepsin · Aplidin
Plitidepsin is a chemotherapy derived from a Mediterranean sea squirt, approved in Australia in 2018 with dexamethasone for multiple myeloma after several other treatments; the European regulator refused it, and it drew attention in 2021 as a possible COVID-19 antiviral.
Similar pages
- PairingChemo-immunotherapy induction → maintenance intensification (SCLC)
Shares IMforte, Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- TrialA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- TrialBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- TrialA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Shares Lurbinectedin basket trial, small-cell lung cancer cohort, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- TrialA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- TrialIDeate-Lung02
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- CompanyJazz Pharmaceuticals
Shares IMforte, ATLANTIS, Lurbinectedin, Ewing sarcoma.
cancers
fronts
drugs
ApprovedCytotoxic (transcription inhibitor)
Lurbinectedin · Zepzelca
EstablishedMarine-derived cyclic depsipeptide (small molecule), intravenous
Plitidepsin · Aplidin
trials
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple MyelomaAplidin - Dexamethasone in Relapsed/Refractory MyelomaATLANTISIMforteLurbinectedin basket trial, small-cell lung cancer cohortStudy of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies